CDK4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer

Cynthia X. Ma, MD, PhD, Washington University School of Medicine, St. Louis, MI, updates us on recent understanding of potential resistance mechanisms to CDK4/6 inhibitors and therapeutic strategies for hormone receptor-positive (HR+) and HER2-negative (HER2-) metastatic breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

• Kategori